Guidelines established by the Quantitative Imaging Biomarkers Alliance (QIBA) Amyloid PET working group, co-chaired by Dawn Matthews of ADMdx and Anne Smith of Siemens Healthineers, have been published. The article in Journal of Neuroscience summarizes the multi-year work of the group, which defined criteria for PET image acquisition and measurement to reduce variability in results. Amyloid is one of two abnormal proteins that are the basis for a diagnosis of Alzheimer’s disease. Its removal is the target of multiple anti-amyloid therapeutics, with two drugs now cleared by the FDA and a third completing its pivotal Phase 3 clinical trials. Controlling the many aspects of acquiring and quantifying amyloid PET scans can allow more accurate planning for clinical trials and interpretation of measured change in successive amyloid PET scans.